AVROBIO (AVRO) Is Now Covered By Morgan Stanley. What can We Expect?

July 16, 2018 - By Kristin Houston

Why Has Morgan Stanley Given AVROBIO (AVRO) a $37.0 Price Target

Analysts at Morgan Stanley has initiated coverage on AVROBIO (AVRO) with a key Overweight rating. The target for AVRO is exactly $37.0. It gives a possible upside of 23.58 % from company’s last price.

The stock increased 6.55% or $1.84 during the last trading session, reaching $29.94. About 115,555 shares traded. AVROBIO, Inc. (AVRO) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral gene therapies to treat rare diseases following a single dose. The company has market cap of $716.67 million. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. It currently has negative earnings. The Company’s lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease.

More notable recent AVROBIO, Inc. (NASDAQ:AVRO) news were published by: Nasdaq.com which released: “AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors” on June 27, 2018, also Streetinsider.com with their article: “UPDATE: AVROBIO, Inc. (AVRO) IPO Opens 54% Higher” published on June 21, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018. More interesting news about AVROBIO, Inc. (NASDAQ:AVRO) were released by: Nasdaq.com and their article: “Nasdaq’s Hot First Day of Summer – Six IPOs Join our Market” published on June 22, 2018 as well as Benzinga.com‘s news article titled: “Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.